Cargando…

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France

OBJECTIVES: To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pialoux, Gilles, Marcelin, Anne-Geneviève, Despiégel, Nicolas, Espinas, Caroline, Cawston, Hélène, Finkielsztejn, Laurent, Laurisse, Audrey, Aubin, Céline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699888/ https://www.ncbi.nlm.nih.gov/pubmed/26714188 http://dx.doi.org/10.1371/journal.pone.0145885

Ejemplares similares

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
por: Despiégel, Nicolas, et al.
Publicado: (2015)

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model
por: Despiegel, Nicolas, et al.
Publicado: (2012)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice
por: Potard, Valérie, et al.
Publicado: (2015)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”
por: Malet, Isabelle, et al.
Publicado: (2018)

Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France
por: Brégigeon-Ronot, Sylvie, et al.
Publicado: (2017)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
por: Brehm, Thomas Theo, et al.
Publicado: (2019)

Chagas Disease, France
por: Lescure, François-Xavier, et al.
Publicado: (2008)

Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France
por: Bruley des Varannes, Stanislas, et al.
Publicado: (2013)

Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

2486. Clinical Outcomes of Patients Treated with Dolutegravir Functional Monotherapy or Dolutegravir plus an Active Non-cytosine Nucleoside Analog: A Retrospective Observational Cohort Study of Treatment-Experienced Patients
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals
por: Hawkins, Kellie, et al.
Publicado: (2018)

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients
por: Gubavu, Camelia, et al.
Publicado: (2016)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain
por: Buzón-Martín, Luis, et al.
Publicado: (2022)

Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model
por: Mandelbrot, Laurent, et al.
Publicado: (2019)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
por: Jabłonowska, Elżbieta, et al.
Publicado: (2019)

Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis
por: Mazzitelli, Maria, et al.
Publicado: (2021)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
por: Mesplède, Thibault, et al.
Publicado: (2013)

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
por: Eron, Joseph J., et al.
Publicado: (2013)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Costs and mortality associated with HIV: a machine learning analysis of the French national health insurance database
por: Prodel, Martin, et al.
Publicado: (2021)

Costs of Conjunctivitis Outbreak, Réunion Island, France
por: Filleul, Laurent, et al.
Publicado: (2018)

Broad-based SARS-CoV-2 testing program for healthcare workers in a primary care hospital in France
por: Chas, Julie, et al.
Publicado: (2021)

Challenges in measuring and valuing productivity costs, and their relevance in mood disorders
por: Lensberg, Benedikte R, et al.
Publicado: (2013)

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART
por: Derache, Anne, et al.
Publicado: (2019)

Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
por: Lee, Sang-Ah, et al.
Publicado: (2018)

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam
por: Bwire, George M., et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t7raefa56laail5qooql3v3dc3